Evidence map›Paper›PMID 29395234›Full record

ArticleSurgery2018

Postoperative complications after resection of borderline resectable and locally advanced pancreatic cancer: The impact of neoadjuvant chemotherapy with conventional radiation or stereotactic body radiation therapy.

Alex B Blair, Lauren M Rosati, Neda Rezaee, Georgios Gemenetzis, Lei Zheng, Ralph H Hruban, John L Cameron, Matthew J Weiss, Christopher L Wolfgang, Joseph M Herman and 1 more

Open access · greenAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Surgery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.1field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Locally Advanced Pancreas Cancer, Is There a Role for Surgery?The Surgical clinics of North America · 2024
    Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Proclivity to Explore Locally Advanced Pancreas Cancer Is Not Associated with Surgeon Volume.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2021
    Article
  17. Article
  18. Borderline resectable pancreatic cancer: Certainties and controversies.World journal of gastrointestinal surgery · 2021
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Alex B BlairDepartment of Surgery, Johns Hopkins Hospital, Baltimore, MD, USA; The Sidney Kimmel Cancer Center, Johns Hopkins Hospital, Baltimore, MD, USA; The Sol Goldman Pancreatic Cancer Center, Johns Hopkins Hospital, Baltimore, MD, USA.
Lauren M RosatiThe Sidney Kimmel Cancer Center, Johns Hopkins Hospital, Baltimore, MD, USA; The Sol Goldman Pancreatic Cancer Center, Johns Hopkins Hospital, Baltimore, MD, USA; Department of Radiation Oncology, Johns Hopkins Hospital, Baltimore, MD, USA.
Neda RezaeeDepartment of Surgery, Johns Hopkins Hospital, Baltimore, MD, USA; The Sidney Kimmel Cancer Center, Johns Hopkins Hospital, Baltimore, MD, USA; The Sol Goldman Pancreatic Cancer Center, Johns Hopkins Hospital, Baltimore, MD, USA.
Georgios GemenetzisDepartment of Surgery, Johns Hopkins Hospital, Baltimore, MD, USA; The Sidney Kimmel Cancer Center, Johns Hopkins Hospital, Baltimore, MD, USA; The Sol Goldman Pancreatic Cancer Center, Johns Hopkins Hospital, Baltimore, MD, USA.
Lei ZhengThe Sidney Kimmel Cancer Center, Johns Hopkins Hospital, Baltimore, MD, USA; The Sol Goldman Pancreatic Cancer Center, Johns Hopkins Hospital, Baltimore, MD, USA; Department of Oncology, Johns Hopkins Hospital, Baltimore, MD, USA.
Ralph H HrubanThe Sidney Kimmel Cancer Center, Johns Hopkins Hospital, Baltimore, MD, USA; The Sol Goldman Pancreatic Cancer Center, Johns Hopkins Hospital, Baltimore, MD, USA; Department of Pathology, Johns Hopkins Hospital, Baltimore, MD, USA.
John L CameronDepartment of Surgery, Johns Hopkins Hospital, Baltimore, MD, USA; The Sidney Kimmel Cancer Center, Johns Hopkins Hospital, Baltimore, MD, USA; The Sol Goldman Pancreatic Cancer Center, Johns Hopkins Hospital, Baltimore, MD, USA.
Matthew J WeissDepartment of Surgery, Johns Hopkins Hospital, Baltimore, MD, USA; The Sidney Kimmel Cancer Center, Johns Hopkins Hospital, Baltimore, MD, USA; The Sol Goldman Pancreatic Cancer Center, Johns Hopkins Hospital, Baltimore, MD, USA.
Christopher L WolfgangDepartment of Surgery, Johns Hopkins Hospital, Baltimore, MD, USA; The Sidney Kimmel Cancer Center, Johns Hopkins Hospital, Baltimore, MD, USA; The Sol Goldman Pancreatic Cancer Center, Johns Hopkins Hospital, Baltimore, MD, USA.
Joseph M HermanDepartment of Radiation Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Jin HeDepartment of Surgery, Johns Hopkins Hospital, Baltimore, MD, USA; The Sidney Kimmel Cancer Center, Johns Hopkins Hospital, Baltimore, MD, USA; The Sol Goldman Pancreatic Cancer Center, Johns Hopkins Hospital, Baltimore, MD, USA. Electronic address: jhe11@jhmi.edu.
Johns Hopkins Hospital · USSidney Kimmel Comprehensive Cancer Center · USSidney Kimmel Cancer Center · USThe University of Texas MD Anderson Cancer Center · US

Funding

Tumor Antigens for Individual Signatures and TherapyP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · PI LENNON, ANNE MARIE · 1993 to 2022
$54.6M
Clinical and Laboratory Research Training for Surgical OncologistsT32CA126607 · NCI · JOHNS HOPKINS UNIVERSITY · PI CAMERON, ANDREW M. · 2008 to 2024
$6.0M
Targeting the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer with a Neoadjuvant Platform Clinical TrialR01CA197296 · NCI · JOHNS HOPKINS UNIVERSITY · PI William Reece Burns, Eric Christenson · 2015 to 2026
$5.7M
NCI NIH HHS P50 CA062924NCI NIH HHS R01 CA197296NCI NIH HHS T32 CA126607
6 · The paper itself

Abstract

backgroundThe impact of neoadjuvant stereotactic body radiation therapy on postoperative complications for patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma remains unclear. Limited studies have compared neoadjuvant stereotactic body radiation therapy versus conventional chemoradiation therapy. A retrospective study was performed to determine if perioperative complications were different among patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma receiving neoadjuvant stereotactic body radiation therapy or chemoradiation therapy.

methodsPatients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma who underwent neoadjuvant chemotherapy with stereotactic body radiation therapy or chemoradiation therapy followed by pancreatectomy at the Johns Hopkins Hospital between 2008 and 2015 were included. Predictive factors for severe complications (Clavien grade ≥ III) were assessed by univariate and multivariate analyses.

resultsA total of 168 patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma underwent neoadjuvant chemotherapy and RT followed by pancreatectomy. Sixty-one (36%) patients underwent stereotactic body radiation therapy and 107 (64%) patients received chemoradiation therapy. Compared with the chemoradiation therapy cohort, the neoadjuvant stereotactic body radiation therapy cohort was more likely to have locally advanced pancreatic ductal adenocarcinoma (62% vs 43% P = .017) and require a vascular resection (54% vs 37%, P = .027). Multiagent chemotherapy was used more commonly in the stereotactic body radiation therapy cohort (97% vs 75%, P < .001). Postoperative complications (Clavien grade ≥ III 23% vs 28%, P = .471) were similar between stereotactic body radiation therapy and chemoradiation therapy cohort. No significant difference in postoperative bleeding or infection was noted in either group.

conclusionCompared with chemoradiation therapy, neoadjuvant stereotactic body radiation therapy appears to offer equivalent rates of perioperative complications in patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma despite a greater percentage of locally advanced disease and more complex operative treatment.

Indexed as

PancreatectomyRadiosurgeryAgedBaltimoreCarcinoma, Pancreatic DuctalFemaleHumansMaleMiddle AgedNeoadjuvant TherapyPancreatic NeoplasmsPostoperative ComplicationsRetrospective Studies

Identifiers

PMID29395234
PMCPMC6220675
OpenAlexW2793310755

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.